SEAGULL HEALTH
Your health,We care!
As the world’s first and only highly selective JAK1 inhibitor, golidocitinib demonstrates significant efficacy in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) with a lower risk of off-target adverse reactions.
AuthenticGuaranteeFast DeliveryPrivacy Golidocitinib is a targeted therapy drug classified as a Janus kinase (JAK) signaling pathway inhibitor. It exerts its therapeutic effect by specifica···【Read More】
Update: 05 Feb,2026Source: Haiou HealthViews: 75
The duration of golidocitinib administration is determined by a comprehensive assessment of the patient’s disease status, treatment response, and drug···【Read More】
Update: 05 Feb,2026Source: Haiou HealthViews: 75
Golidocitinib is a JAK/STAT signaling pathway inhibitor, mainly used for the treatment of relapsed or refractory T-cell lymphoma. Its common adverse r···【Read More】
Update: 05 Feb,2026Source: Haiou HealthViews: 78
The dosage and administration of golidocitinib must be strictly prescribed by a physician. Dosing is generally adjusted based on the patient’s disease···【Read More】
Update: 05 Feb,2026Source: Haiou HealthViews: 78
Golidocitinib is an oral targeted therapeutic agent indicated for the treatment of relapsed or refractory Peripheral T-Cell Lymphoma (PTCL). It inhibi···【Read More】
Update: 05 Feb,2026Source: Haiou HealthViews: 81
Golidocitinib is a highly selective JAK inhibitor, currently indicated for adult patients with relapsed or refractory peripheral T-cell lymphoma (R/R ···【Read More】
Update: 05 Feb,2026Source: Haiou HealthViews: 72
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
